Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals Inc is reported as having 2,876,407 shares of Class A Common Stock beneficially owned by SilverArc Capital Management, LLC and Devesh Gandhi, representing 5.6% of the class as of 03/31/2026.
The filing states SilverArc acts as investment adviser to multiple funds that together account for the disclosed position, with specific allocations to named funds listed in the report.
KalVista Pharmaceuticals, Inc. chief executive Benjamin L. Palleiko reported routine equity compensation activity and related tax sales. On May 11, 2026, he exercised 7,120 restricted stock units, receiving an equal number of common shares for no cash cost as the units vested.
On May 12, 2026, he sold 3,322 common shares at $26.71 per share to cover tax withholding obligations from this vesting. A footnote explains this “sell to cover” transaction did not represent a discretionary sale decision. After these transactions, he directly owned 466,375 common shares, with additional RSUs remaining outstanding.
Skyline Merger Sub, Inc., a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., is offering to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. for $27.00 per share in cash pursuant to the Offer to Purchase dated May 13, 2026.
The Company reported 53,240,888 Shares outstanding as of May 6, 2026. The Schedule TO also lists 4,789,390 options, 3,686,552 restricted stock units, 46,104 ESPP purchase rights, 1,630,000 warrants, and 8,551,960 Shares reserved for conversion of the convertible senior notes. The Merger Agreement dated April 29, 2026 among Parent, Purchaser, the Company and KalVista UK is incorporated by reference.
Chiesi Farmaceutici and its subsidiary Skyline Merger Sub have outlined a proposed cash tender offer to acquire KalVista Pharmaceuticals for $27.00 per share under an Agreement and Plan of Merger dated April 28, 2026. The communication is a preliminary solicitation and states the Offer has not yet commenced.
The filing says Offer materials (a Schedule TO by Parent and Purchaser and a Schedule 14D-9 by KalVista) will be filed with the SEC when the Offer is launched; investors are directed to review those materials and the companies' SEC filings for details.
KalVista Pharmaceuticals, Inc. Schedule 13G/A amendment discloses passive, shared voting and dispositive power over 1,546,105 shares (3.0%) by Integrated Core Strategies (US) LLC and 1,912,146 shares (3.7%) by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing is a joint filing under a Joint Filing Agreement dated April 30, 2026.
The filing lists shared voting and disposition powers and clarifies the securities are held by entities subject to Millennium-related voting or investment discretion; signatures are provided by Gil Raviv and Israel A. Englander.
KalVista Pharmaceuticals, Inc. filed Amendment No. 1 to its transition Form 10-KT to add the disclosures required by Part II and Part III and to furnish new Section 302 certifications. The Amendment also discloses that on April 29, 2026 the company and certain subsidiaries entered into an Agreement and Plan of Merger providing for the acquisition of KalVista by Chiesi Farmaceutici S.p.A. through a merger in which KalVista will become a wholly owned subsidiary of Chiesi.
The Amendment restates that its Original Filing continues to speak as of the Original Filing date and that no other updates were made. It includes board and executive officer biographies, executive compensation disclosures for the 2025 transition period, equity plan and outstanding award tables, related-party transactions (including participation by certain holders in the November 2024 offering), and auditor fee disclosures.
KalVista Pharmaceuticals agreed to be acquired by Chiesi Group in an all-cash transaction. Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share, implying a total deal value of about $1.9 billion.
The offer is conditioned on a majority of shares being tendered, antitrust and foreign investment clearances, and customary accuracy, covenant and no–material-adverse-effect conditions. After the tender offer, a back-end merger under Section 251(h) of Delaware law will make KalVista a wholly owned Chiesi subsidiary.
KalVista’s board unanimously approved the merger agreement and recommends stockholders tender their shares. The agreement includes typical non-solicitation and fiduciary out provisions and a $66.4 million termination fee payable to Chiesi in specified circumstances. The parties expect closing in Q3 2026, subject to conditions.
KalVista Pharmaceuticals chief medical officer Paul K. Audhya reported routine equity compensation activity and a related tax sale. On April 16, 6,250 restricted stock units vested into the same number of common shares at no cost, as part of a scheduled RSU vesting plan. A total of 2,686 common shares were then sold at an average price of $20.2163 solely to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. After these transactions, he directly holds 142,547 shares of common stock and 93,750 unvested RSUs that continue to vest quarterly, subject to continued service.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity and a related tax sale. On April 16, 2026, 6,250 restricted stock units converted into an equal number of common shares at no cost, reflecting RSU vesting. On April 17, 2026, 1,862 common shares were sold at $20.2163 per share solely to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. After these transactions, Sweeny directly held 51,391 shares of KalVista common stock. The RSU award vests in 16 equal quarterly installments starting on April 16, 2026, subject to continued service.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity. On April 16, 2026, 6,250 restricted stock units (RSUs) converted into the same number of common shares for no cash consideration, reflecting scheduled vesting. On April 17, 2026, he sold 1,862 common shares at $20.2163 per share in an open-market transaction specifically to cover tax withholding obligations from the RSU vesting, described as a nondiscretionary “sell to cover” sale. After these transactions, he directly held 18,150 common shares, and 93,750 RSUs remained outstanding, which continue to vest quarterly in 1/16 increments starting April 16, 2026, subject to continued service.